e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Lung cancer: treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC)
M. Donghi, P. Antonelli, R. Giura (Como, Italy)
Source:
Annual Congress 2002 - Lung cancer: treatment
Session:
Lung cancer: treatment
Session type:
Thematic Poster Session
Number:
2928
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Donghi, P. Antonelli, R. Giura (Como, Italy). Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC). Eur Respir J 2002; 20: Suppl. 38, 2928
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S)
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002
The comparison of paclitaxel-carboplatin (PCp) versus gemcitabine-cisplatin (GC) in the treatment of locally advanced or metastatic non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC).
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
A phase 2 study of induction carboplatin (CBDCA) and dosetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 375s
Year: 2001
LATE-BREAKING ABSTRACT: Triplet chemotherapy (paclitaxel/gemcitabine/cisplatin) is more active in advanced squamous cell subtype (SCC) non-small cell lung cancer (NSCLC) than doublet treatment (vinorelbine/cisplatin): A randomized phase III trial in 443 NSCLC patients
Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions
Year: 2012
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002
Front-line weekly gemcitabine (G) for unfit or elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed (Pem) for advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Benefit of immune checkpoint inhibitors (ICIs) for second-line treatment of advanced non-small cell lung cancer (NSCLC) using restricted mean survival time (RMST).
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
The results of gefitinib (Iressa) treatment in 89 patients with advanced non-small cell lung cancer (NSCLC) on expanded access programme (EAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 753s
Year: 2006
Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC)
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
Use of adjuvants to chemotherapy in stage IV nonsmall cell lung carcinoma (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
A phase I trial of combined carboplatin and topotecan as 2
nd
line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept